Patents by Inventor Kevin Wayne Kuntz

Kevin Wayne Kuntz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240368167
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: April 18, 2024
    Publication date: November 7, 2024
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • Publication number: 20240325391
    Abstract: The present invention is directed to dosing, dosage regimens, formulations, unit dosage forms, and related, of a PARP7 inhibitor for the treatment of cancer. The present invention is also directed to methods of treating cancer by administering the PARP7 inhibitor in combination with an antibody that binds to PD-1.
    Type: Application
    Filed: September 22, 2023
    Publication date: October 3, 2024
    Inventors: Melissa Marie Vasbinder, Lucas J. Utley, Viviana Bozon, Kevin Wayne Kuntz, Sudha Parasuraman, William McCulloch, Nolan Wood
  • Publication number: 20240279224
    Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: February 28, 2024
    Publication date: August 22, 2024
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • Publication number: 20240190844
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 13, 2024
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Laurie B. Schenkel, Kevin Wayne Kuntz
  • Publication number: 20240165121
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 23, 2023
    Publication date: May 23, 2024
    Inventors: Kevin Wayne KUNTZ, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • Patent number: 11987584
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: May 21, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • Patent number: 11958837
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: April 16, 2024
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger
  • Patent number: 11952377
    Abstract: The present invention relates to bicyclic heterocycle compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: April 9, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer Downing, Kevin Wayne Kuntz, Laurie B. Schenkel, Melissa Marie Vasbinder
  • Publication number: 20240101540
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 28, 2024
    Inventors: Nicholas Robert Perl, Kevin Wayne Kuntz, Jennifer Downing
  • Publication number: 20240051946
    Abstract: The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 15, 2024
    Inventors: Nicholas Robert Perl, Kevin Wayne Kuntz
  • Publication number: 20240034728
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: May 12, 2023
    Publication date: February 1, 2024
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • Publication number: 20230312586
    Abstract: The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 5, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Nicholas Robert Perl, Jennifer Downing
  • Publication number: 20230303542
    Abstract: The present invention relates to solid forms of the poly(ADP-ribose) polymerase 14 (PARP14) inhibitor 7-((1-acetylpiperidin-4-yl)methoxy)-5-fluoro-2-(((tetrahydro-2H-pyran-4-yl)thio)methyl)quinazolin-4(3H)-one, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: February 8, 2023
    Publication date: September 28, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz, Nicholas Robert Perl, John Alphons Kremers, Zheng Jane Li, Pengyuan Chen
  • Patent number: 11691969
    Abstract: The present invention relates to pyridazinones and related compounds having Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 4, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Nicholas Robert Perl, Melissa Marie Vasbinder, Kevin Wayne Kuntz
  • Publication number: 20230192664
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Application
    Filed: October 27, 2022
    Publication date: June 22, 2023
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Patent number: 11642348
    Abstract: The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Kevin Wayne Kuntz, John Emmerson Campbell, Masashi Seki, Syuji Shirotori, Wataru Itano, Wanjun Zheng
  • Publication number: 20230140327
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 29, 2022
    Publication date: May 4, 2023
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Publication number: 20230101819
    Abstract: The present disclosure provides carboxamides and sulfonamides having Formula (I); and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
    Type: Application
    Filed: November 22, 2021
    Publication date: March 30, 2023
    Inventors: Megan Alene Cloonan FOLEY, Kevin Wayne KUNTZ, James Edward John MILLS, Lorna Helen MITCHELL, Michael John MUNCHHOF, Darren Martin HARVEY
  • Patent number: 11566020
    Abstract: The present invention relates to pyridazinones and related compounds which are inhibitors of PARP7 and are useful in the treatment of cancer.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: January 31, 2023
    Assignee: Ribon Therapeutics, Inc.
    Inventors: Melissa Marie Vasbinder, Laurie B. Schenkel, Kerren Kalai Swinger, Kevin Wayne Kuntz
  • Publication number: 20230018702
    Abstract: The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: April 14, 2021
    Publication date: January 19, 2023
    Inventors: Laurie B. Schenkel, Melissa Marie Vasbinder, Kevin Wayne Kuntz, Kerren Kalai Swinger